Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer

Transl Lung Cancer Res. 2024 Jun 30;13(6):1444-1449. doi: 10.21037/tlcr-24-111. Epub 2024 Jun 18.
No abstract available

Keywords: Subcutaneous (SC); atezolizumab; immune checkpoint inhibitors (ICIs); intravenous (IV); non-small cell lung cancer (NSCLC).

Publication types

  • Editorial
  • Comment